Scientific Advisory Board

Portola’s Scientific Advisory Board provides advice to Portola on all aspects of therapeutic development—from unmet medical needs, to new targets and paths, to target validation, to optimal indications, patient populations and trial design. Scientific Advisory Board members also help connect Portola to specific expertise as needed and continually challenge the company to base its therapeutic programs on the best science and critical thinking.

  • SHAUN COUGHLIN, M.D., Ph.D.
    Director, Cardiovascular Research Institute and
    Director, Daiichi Research Center, University of California, San Francisco
  • CHARLES ESMON, Ph.D.
    Head of the Coagulation Biology Laboratory at the Oklahoma Medical Research Foundation
  • DAVID GINSBURG, M.D.
    James V. Neel Distinguished University Professor of Internal Medicine and Human Genetics, and Warner-Lambert/Parke-Davis Professor of Medicine, University of Michigan Medical School
    Howard Hughes Medical Institute Investigator
  • FRANK MCCORMICK, Ph.D.
    Director, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
    E. Dixon Heise Distinguished Professorship in Oncology and David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research, University of California, San Francisco
  • ARTHUR WEISS, M.D., Ph.D.
    Chief, Rheumatology, University of California San Francisco
    Director, Medical Scientist Training Program, University of California San Francisco

SHAUN COUGHLIN, M.D., Ph.D.
Director, Cardiovascular Research Institute and
Director, Daiichi Research Center, University of California, San Francisco

Dr. Shaun Coughlin is Director of the Cardiovascular Research Institute, Director of the Daiichi Research Center and a Distinguished Professor of Cardiovascular Biology and Medicine, all programs that stem from the University of California, San Francisco. Dr. Coughlin’s marked accomplishments include his election into the National Academy of Sciences and numerous awards presented by the American Heart Association, including the Basic Science Prize and the Hoeg Award.

Back to top

CHARLES ESMON, Ph.D.
Head of the Coagulation Biology Laboratory at the Oklahoma Medical Research Foundation 

Dr. Charles Esmon is a member of the National Academy of Sciences, an investigator at the Howard Hughes Medical Institute, and Head of the Coagulation Biology Laboratory at the Oklahoma Medical Research Foundation. He has more than 300 publications related to blood coagulation and inflammation and has served as a consultant with a number of large and small pharmaceutical companies. Among his contributions in the coagulation area were the identification of thrombomodulin (with Dr. Whyte Owen) and endothelial protein C receptor (with Dr. Kenji Fukudome). In the field of sepsis, he and Dr. Fletcher Taylor were the first to show that activated protein C could prevent and treat septic animals challenged with normally lethal levels of bacteria. Most recently, he has shown that cell death can trigger multi-organ failure by releasing DNA/histone complexes that cause multi-organ failure, a process that can be blocked by inhibiting the toxic histones. 

Back to top

DAVID GINSBURG, M.D.
James V. Neel Distinguished University Professor of Internal Medicine and Human Genetics, and Warner-Lambert/Parke-Davis Professor of Medicine, University of Michigan Medical School Howard Hughes Medical Institute Investigator 

Dr. David Ginsburg is James V. Neel Distinguished University Professor of Internal Medicine and Human Genetics, Warner-Lambert/Parke-Davis Professor of Medicine and a member of the Life Sciences Institute at the University of Michigan Medical School. He also is a Howard Hughes Medical Institute Investigator. For the past 25 years, he has dedicated his career to understanding the components of the blood-clotting system and how disturbances in their function lead to human bleeding and blood-clotting disorders. His lab has studied the molecular basis of the common disorder von Willebrand disease and is identifying modifier genes that control severity for this and related diseases. His lab has also defined mutations in ADAMTS13, an enzyme that processes von Willebrand factor, as the cause of thrombotic thrombocytopenia purpura. Studies of the bleeding disease combined deficiency of factors V and VIII by his lab identified mutations in a novel pathway for the transport of a select subset of proteins from the ER to the Golgi. Dr. Ginsburg is a member of the Institute of Medicine of the National Academy of Sciences, and the American Academy of Arts and Sciences. 

Back to top

FRANK MCCORMICK, Ph.D.
Director, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
E. Dixon Heise Distinguished Professorship in Oncology and David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research, University of California, San Francisco
 

Dr. Frank McCormick is an internationally renowned molecular biologist and cancer researcher who helped pave the way toward the development of targeted cancer therapies. He is Director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center and has led the UCSF Cancer Center program since its inception in 1998. He holds the E. Dixon Heise Distinguished Professorship in Oncology and the David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research at UCSF. He is also the Associate Dean of the UCSF School of Medicine and a distinguished Professor in Residence in the Department of Microbiology and Immunology as well as in the Department of Biochemistry and Biophysics. He is president-elect of the American Association for Cancer Research, an elected member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the Royal Society. 

Back to top

ARTHUR WEISS M.D., Ph.D.
Chief, Rheumatology, University of California San Francisco
Director, Medical Scientist Training Program, University of California San Francisco
 

Dr. Arthur Weiss is Chief of the Division of Rheumatology and Director of the Medical Scientist Training Program, both at the University of California San Francisco. Dr. Weiss was named an Ephraim P. Engleman Distinguished Professor and is a member of the U.S National Academy of Sciences, Institute of Medicine and the American Academy of Arts and Sciences. 

Back to top